80 related articles for article (PubMed ID: 29720733)
1. Adding dasatinib to intensive treatment in core-binding factor acute myeloid leukemia-results of the AMLSG 11-08 trial.
Paschka P; Schlenk RF; Weber D; Benner A; Bullinger L; Heuser M; Gaidzik VI; Thol F; Agrawal M; Teleanu V; Lübbert M; Fiedler W; Radsak M; Krauter J; Horst HA; Greil R; Mayer K; Kündgen A; Martens U; Heil G; Salih HR; Hertenstein B; Schwänen C; Wulf G; Lange E; Pfreundschuh M; Ringhoffer M; Girschikofsky M; Heinicke T; Kraemer D; Göhring G; Ganser A; Döhner K; Döhner H
Leukemia; 2018 Jul; 32(7):1621-1630. PubMed ID: 29720733
[TBL] [Abstract][Full Text] [Related]
2. The core concepts of core binding factor acute myeloid leukemia: Current considerations for prognosis and treatment.
Darwish C; Farina K; Tremblay D
Blood Rev; 2023 Nov; 62():101117. PubMed ID: 37524647
[TBL] [Abstract][Full Text] [Related]
3. Low-dose azacitidine, pioglitazone and all-
Heudobler D; Luke F; Hahn J; Grube M; Schlosser P; Kremers S; Sudhoff T; Westermann J; Hutter-Kronke ML; Schlenk RF; Weber D; Paschka P; Zeman F; Dohner H; Herr W; Reichle A; Thomas S
Haematologica; 2024 Apr; 109(4):1274-1278. PubMed ID: 37881883
[No Abstract] [Full Text] [Related]
4. Myeloid neoplasms post cytotoxic therapy: epidemiology, pathogenesis outcomes, prognostic factors, and treatment options.
Ma J; Wang Y
Ann Med; 2024 Dec; 56(1):2329132. PubMed ID: 38608646
[TBL] [Abstract][Full Text] [Related]
5. Literature review and expert opinion on the treatment of high-risk acute myeloid leukemia in patients who are eligible for intensive chemotherapy.
Palmieri R; Billio A; Ferrara F; Galimberti S; Lemoli RM; Todisco E; Moretti F; Venditti A
Front Oncol; 2024; 14():1367393. PubMed ID: 38444680
[TBL] [Abstract][Full Text] [Related]
6. Hypomethylating agent monotherapy in core binding factor acute myeloid leukemia: a French multicentric retrospective study.
Gabellier L; Peterlin P; Thepot S; Hicheri Y; Paul F; Gallego-Hernanz MP; Bertoli S; Turlure P; Pigneux A; Guieze R; Ochmann M; Malfuson JV; Cluzeau T; Thomas X; Tavernier E; Jourdan E; Bonnet S; Tudesq JJ; Raffoux E
Ann Hematol; 2024 Mar; 103(3):759-769. PubMed ID: 38273140
[TBL] [Abstract][Full Text] [Related]
7. Improving long-term outcomes with intensive induction chemotherapy for patients with AML.
Röllig C
Hematology Am Soc Hematol Educ Program; 2023 Dec; 2023(1):175-185. PubMed ID: 38066853
[TBL] [Abstract][Full Text] [Related]
8. Combination of eriocalyxin B and homoharringtonine exerts synergistic anti-tumor effects against t(8;21) AML.
Lei YC; Chen XJ; Dai YT; Dai B; Wang JY; Li MH; Liu P; Liu H; Wang KK; Jiang L; Chen B
Acta Pharmacol Sin; 2024 Mar; 45(3):633-645. PubMed ID: 38017299
[TBL] [Abstract][Full Text] [Related]
9. Allosteric SHP2 inhibition increases apoptotic dependency on BCL2 and synergizes with venetoclax in FLT3- and KIT-mutant AML.
Popescu B; Stahlhut C; Tarver TC; Wishner S; Lee BJ; Peretz CAC; Luck C; Phojanakong P; Camara Serrano JA; Hongo H; Rivera JM; Xirenayi S; Chukinas JA; Steri V; Tasian SK; Stieglitz E; Smith CC
Cell Rep Med; 2023 Nov; 4(11):101290. PubMed ID: 37992684
[TBL] [Abstract][Full Text] [Related]
10. An Overview of Targeted Therapies in Acute Myeloid Leukemia.
Turkalj S; Radtke FA; Vyas P
Hemasphere; 2023 Jun; 7(6):e914. PubMed ID: 37304938
[TBL] [Abstract][Full Text] [Related]
11. Outcome and prognostic factors of CBF pediatric AML patients with t(8;21) differ from patients with inv(16).
Qiu KY; Liao XY; Li Y; Huang K; Xu HG; Fang JP; Zhou DH
BMC Cancer; 2023 May; 23(1):476. PubMed ID: 37231380
[TBL] [Abstract][Full Text] [Related]
12. Maintenance therapy in acute myeloid leukemia: advances and controversies.
Senapati J; Kadia TM; Ravandi F
Haematologica; 2023 Sep; 108(9):2289-2304. PubMed ID: 37139599
[TBL] [Abstract][Full Text] [Related]
13. Therapy-related core binding factor acute myeloid leukemia.
George B; Yohannan B; Mohlere V; Gonzalez A
Int J Hematol Oncol; 2023 Feb; 12(1):IJH43. PubMed ID: 36874378
[TBL] [Abstract][Full Text] [Related]
14. A case report of sudden cardiac arrest and torsade de pointes induced by the second-generation tyrosine kinase inhibitor dasatinib combined with fluconazole.
Yuan Y; Wang C; Yao H
Front Cardiovasc Med; 2023; 10():984572. PubMed ID: 36873392
[TBL] [Abstract][Full Text] [Related]
15. Midostaurin in addition to intensive chemotherapy in acute myeloid leukemia with t(8;21) and
Ruhnke L; Röllig C; Herold S; Sauer T; Brandts CH; Steffen B; Schäfer-Eckart K; Krause SW; Hänel M; Reichle A; Scholl S; Neubauer A; Mikesch JH; Schetelig J; Stölzel F; Kramer M; Haake A; Frimmel J; Krämer A; Schlenk R; Platzbecker U; Serve H; Baldus CD; Müller-Tidow C; Aust D; Bornhäuser M; Ehninger G; Thiede C
Haematologica; 2023 Sep; 108(9):2520-2525. PubMed ID: 36779591
[No Abstract] [Full Text] [Related]
16. Pediatric Acute Myeloid Leukemia Post Cytotoxic Therapy-Retrospective Analysis of the Patients Treated in Poland from 2005 to 2022.
Czogała M; Czogała W; Pawińska-Wąsikowska K; Książek T; Bukowska-Strakova K; Sikorska-Fic B; Łaguna P; Skalska-Sadowska J; Wachowiak J; Rodziewicz-Konarska A; Moj-Hackemer M; Kałwak K; Muszyńska-Rosłan K; Krawczuk-Rybak M; Fałkowska A; Drabko K; Kozłowska M; Irga-Jaworska N; Bobeff K; Młynarski W; Tomaszewska R; Szczepański T; Chodała-Grzywacz A; Karolczyk G; Mycko K; Badowska W; Zielezińska K; Urasiński T; Bartoszewicz N; Styczyński J; Balwierz W; Skoczeń S
Cancers (Basel); 2023 Jan; 15(3):. PubMed ID: 36765692
[TBL] [Abstract][Full Text] [Related]
17. Identification and in silico analysis of noval alteration Arg420Gly in KIT proto oncogene among acute myeloid leukemia patients.
Akram AM; Hassan M; Chaudhary A; Hayat S; Ali Q; Hussain T; Zafar A; Javed MA
Sci Rep; 2022 Nov; 12(1):19252. PubMed ID: 36357474
[TBL] [Abstract][Full Text] [Related]
18. The Cup Runneth Over: Treatment Strategies for Newly Diagnosed Acute Myeloid Leukemia.
Cooperrider JH; Shukla N; Nawas MT; Patel AA
JCO Oncol Pract; 2023 Feb; 19(2):74-85. PubMed ID: 36223559
[TBL] [Abstract][Full Text] [Related]
19. Acute myeloid leukemia with variant t(8;10;21).
Bacova B; Sobotka J; Kacirkova P; Rivnacova V; Karlova/Zubata I; Novak J
Leuk Res Rep; 2022; 18():100350. PubMed ID: 36158314
[TBL] [Abstract][Full Text] [Related]
20. Precision Medicine in Myeloid Malignancies: Hype or Hope?
Upadhyay Banskota S; Khanal N; Marar RI; Dhakal P; Bhatt VR
Curr Hematol Malig Rep; 2022 Dec; 17(6):217-227. PubMed ID: 35972641
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
